Dr. Shah Discusses Sequencing for MCL
Bijal D. Shah, MD
Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the sequencing of agents for patients with mantle cell lymphoma (MCL).
Sequencing will play a role in determining which treatments to give to patients with MCL. According to Shah, clinically, a patient with a p53 mutation should first receive lenalidomide (Revlimid).
The next big biomarker will be the ColonoSEQTM minimal residual disease (MRD) approach to assess death of remission, explains Shah.